From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
PAK4-IN-2 is a highly potent PAK4 inhibitor with IC50 value of 2.7 nM. PAK4-IN-2 can arrest MV4-11 cells at G0/G1 phase and induce cell apoptosis. PAK4-IN-2 can be used for researching cancer .
PAK1-IN-1 is a potent and selective PAK1 inhibitor with an IC50 of 9.8 nM. PAK1-IN-1 inhibits the migration and invasion of PAK1-related tumour cells in a dose-dependent manner .
PAK4-IN-1 (Compound 19) is a potent, selective, orally active PAK4 inhibitor with robust anti-tumor efficacy in vivo. PAK4-IN-1 is stable under both acidic and neutral conditions .
PAK4-IN-3(compound 27e) is aPAK4inhibitor, with theIC50of 10 nM.PAK4-IN-3shows antiproliferative activity against A549 cells with anIC50value of 0.61μM, and inducesapoptosisof A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1 .
Pak6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAK1 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAK2 Rat Pre-designed siRNA Set A contains three designed siRNAs for PAK2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAK5 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAK6 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pak6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAK1IP1 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK1IP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TAT-PAK18 inhibitory peptide is a membrane-permeable PAK inhibitory peptide. TAT-PAK18 inhibitory peptide reduces F-actin clusters and occludes the effect of Shank3 knockdown .
NVS-PAK1-C is a potent, ATP-competitive and specific allosteric PAK1 inhibitor probe with IC50 values of 5 nM and 6 nM for dephosphorylated PAK1 and phosphorylated PAK1, respectively. NVS-PAK1-C is also against dephosphorylated PAK2 (IC50=270 nM) and phosphorylated PAK2 (IC50=720 nM) .
ZMF-10 is a highly potent PAK1 inhibitor, with IC50s of 174 nM, 1.038 μM and 1.372 μM for PAK1, PAK2 and PAK3, respectively. ZMF-10 can inhibit PAK1 activity to affect PAK1-regulated apoptosis, ER-Stress and migration in MDA-MB-231 cells. ZMF-10 can be used for researching anticancer .
AZ13705339 is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 can be used in the research of cancers .
AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers .
LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC50 of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis .
Padnarsertib (KPT-9274) is an orally bioavailable, dual PAK4/Nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with IC50s of <100 nM and 120 nM, respectively .
MRIA9 is an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor, with IC50 values of 516 nM, 180 nM and 127 nM for SIK1, SIK2 and SIK3, respectively .
KY-04031 is a potent PAK4 inhibitor with IC50 of 0.79 μM. KY-04031 binds to the ATP-binding pocket of PAK4. KY-04031 blocks tumor cell growth and invasion .
ZMF-23 is a PAK1/HDAC6 dual inhibitor. ZMF-23 inhibits PAK1 and HDAC6 regulated aerobic glycolysis and migration. ZMF-23 induces TNF-α-regulated necroptosis, and further enhances apoptosis. ZMF-23 inhibits the Warburg effect and cell migration. ZMF-23 can be used for research of triple-negative breast cancer (TNBC) .
PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant .
ZINC194100678 is a potent PAK1 inhibitor with an IC50 value of 8.37 μM. ZINC194100678 can inhibit MDA-MB-231 cell proliferation. ZINC194100678 can be used for researching anticancer .
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
Mesalamine impurity P is an impurity of Mesalamine (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
Fingolimod-d4 (hydrochloride) is the deuterium labeled Fingolimod hydrochloride. Fingolimod hydrochloride (FTY720) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride (FTY720) also is a pak1 activator, a immunosuppressant[1].
5-Aminosalicylic Acid-d3 (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].
5-Aminosalicylic acid-d3 is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[1][2][3][4].
5-Aminosalicylic acid- 13C6 is the 13C labeled 5-Aminosalicylic Acid[1]. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[2][3][4].
AZA197 is a selective small molecule inhibitor of Cdc42.AZA197 suppresses colon cancer cell proliferation, cell migration, invasion and increases apoptosis by down-regulating the PAK1 and ERK signaling pathways in vitro. AZA197 reduces tumor growth and significantly increases mouse survival in SW620 tumor xenografts .
EHop-016 is a potent and selective Rac GTPase Rac1 and Rac3 inhibitor. EHop-016 inhibits Rac1 activity with an IC50 of 1.1 μM in MDA-MB-435 cells. EHop-016 inhibits Vav2 interaction with Rac, Rac-activated PAK1, lamellipodia formation, and cell migration .
Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator .
Fingolimod (hydrochloride) (Standard) is the analytical standard of Fingolimod (hydrochloride). This product is intended for research and analytical applications. Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator .
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
TAT-PAK18 inhibitory peptide is a membrane-permeable PAK inhibitory peptide. TAT-PAK18 inhibitory peptide reduces F-actin clusters and occludes the effect of Shank3 knockdown .
TAT-PAK18 R192A is an inactive Tat-Pak peptide. TAT-PAK18 R192A does not have any effect in the translocation of Rac1 triggered by any of the interrogated proteins .
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
PAK1 is a dynamic protein kinase that plays an important role in multiple intracellular signaling pathways, affecting cytoskeletal dynamics, adhesion, migration, proliferation, apoptosis, mitosis, and vesicle trafficking. Multifunctional PAK1 directly phosphorylates BAD to provide antiapoptotic cell protection. PAK1 Protein, Human (His-SUMO) is the recombinant human-derived PAK1 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag. The total length of PAK1 Protein, Human (His-SUMO) is 545 a.a., with molecular weight of ~76.6 kDa.
PAK6, a dynamic serine/threonine kinase, regulates gene transcription activated by AR or MAP2K6/MAPKK6. It phosphorylates and inhibits AR-mediated transcription, hindering ESR1-mediated transcription. PAK6 interacts with IQGAP1, suggesting a role in cytoskeleton regulation. Moreover, it protects cells from apoptosis by phosphorylating BAD, showcasing its multifaceted impact on transcriptional control and cytoskeletal dynamics. PAK6 Protein, Human is the recombinant human-derived PAK6 protein, expressed by E. coli , with tag free. The total length of PAK6 Protein, Human is 292 a.a., .
PAK6, a dynamic serine/threonine kinase, regulates gene transcription activated by AR or MAP2K6/MAPKK6. It phosphorylates and inhibits AR-mediated transcription, hindering ESR1-mediated transcription. PAK6 interacts with IQGAP1, suggesting a role in cytoskeleton regulation. Moreover, it protects cells from apoptosis by phosphorylating BAD, showcasing its multifaceted impact on transcriptional control and cytoskeletal dynamics. PAK6 Protein, Human (His) is the recombinant human-derived PAK6 protein, expressed by E. coli , with N-6*His labeled tag. The total length of PAK6 Protein, Human (His) is 292 a.a., .
PAK5 is a dynamic serine/threonine kinase that affects cytoskeletal regulation, cell migration, proliferation, and survival through multiple pathways. Activation triggers autophosphorylation, affecting RAF1 kinase activity and promoting cell survival through BAD phosphorylation. PAK5 Protein, Human (Baculovirus, His) is the recombinant human-derived PAK5 protein, expressed by Sf9 insect cells , with N-6*His labeled tag. The total length of PAK5 Protein, Human (Baculovirus, His) is 293 a.a., with molecular weight of ~34.9 kDa.
PAK3 is a serine/threonine kinase that plays a key role in multiple signaling pathways, affecting cytoskeletal dynamics, cell migration, and cell cycle. Its involvement in dendritic spine morphogenesis and synapse formation emphasizes its importance in neuronal processes. PAK3 Protein, Human (sf9, His) is the recombinant human-derived PAK3 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of PAK3 Protein, Human (sf9, His) is 544 a.a., with molecular weight of ~60 kDa.
PAK4 is an important serine/threonine kinase that affects cytoskeletal regulation, cell migration, growth, and survival through multiple pathways. Activation triggered by various effectors induces autophosphorylation, targeting proteins such as SSH1 and LIMK1 to regulate cofilin activity and stabilize actin filaments. PAK4 Protein, Human (His-SUMO) is the recombinant human-derived PAK4 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag. The total length of PAK4 Protein, Human (His-SUMO) is 426 a.a., with molecular weight of 63.9 kDa.
PAK4; p21 protein (Cdc42/Rac)-activated kinase 4; p21(CDKN1A) activated kinase 4; serine/threonine-protein kinase PAK 4; PAK-4; p21-activated kinase 4; p21(CDKN1A)-activated kinase 4; protein kinase related to S. cerevisiae STE20, effector for Cdc42Hs
Fingolimod-d4 (hydrochloride) is the deuterium labeled Fingolimod hydrochloride. Fingolimod hydrochloride (FTY720) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride (FTY720) also is a pak1 activator, a immunosuppressant[1].
5-Aminosalicylic Acid-d3 (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].
5-Aminosalicylic acid-d3 is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[1][2][3][4].
5-Aminosalicylic acid- 13C6 is the 13C labeled 5-Aminosalicylic Acid[1]. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[2][3][4].
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
PAK2 Antibody (YA695) is a non-conjugated and Mouse origined monoclonal antibody about 58 kDa, targeting to PAK2 (7H3). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Monkey.